Stipple Bio

Executive Summary

Stipple Bio is a private San Diego-based company founded in 2021, focused on unlocking cellular profiling and target discovery with epitope resolution. Operating at the intersection of oncology and immunology, the company aims to provide high-resolution characterization of immune cells and tumor microenvironments. Despite limited public information, Stipple Bio appears to be in an early stage, likely pre-revenue, with a platform that could enable novel biomarker and target identification. The company has not disclosed funding or partnerships, but its niche in epitope-resolution profiling positions it for potential applications in precision medicine and immunotherapy development. Given the early stage, the conviction score is moderate, reflecting the uncertainty around commercialization and competitive positioning.

Upcoming Catalysts (preview)

• Q2 2027Series A Funding Announcement60% success
• Q4 2027First Major Pharmaceutical Partnership40% success
• Q1 2027Publication of Platform Validation Data in Peer-Reviewed Journal70% success